Can a new drug called ZP9830 calm psoriasis Flare-Ups?

NCT ID NCT07733089

Recruiting now Symptom relief Sponsor: Zealand Pharma Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether an experimental drug, ZP9830, can safely improve symptoms of plaque psoriasis when taken over 8 weeks. The study includes adults with stable plaque psoriasis who have at least two visible plaques. Researchers will monitor side effects, measure how the drug moves through the body, and check for any reduction in skin plaques.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called ZP9830
What this could lead to: If it works, this could point toward a new treatment option for plaque psoriasis that reduces skin plaques and symptoms.
What could go wrong: This is an early-phase trial with only 32 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Show contact details

Locations

Centre for Human Drug Research
RECRUITING

Leiden, South Holland, 2333 CL, Netherlands

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.